Tectonic 10-Q: $21.3M Q3 Loss, $234.7M Cash, $22.3M Net ATM Proceeds
TECX sits 25% above its 52-week low of $15.52.
Summary
Tectonic's Q3 10-Q confirms the $21.3M quarterly loss and $234.7M cash position reported in today's 8-K, and details $22.3M of net ATM proceeds from 660,492 shares sold in the quarter at a $34.45 average.
Key Events · Earnings and Guidance · TECX
-
Q3 Loss Widens on Higher R&D
Net loss was $21.3 million versus $19.0 million a year earlier; R&D rose to $17.4 million from $16.9 million and G&A to $6.0 million from $5.0 million.
-
ATM Sold $22.3M Net in Q3
660,492 shares sold at a $34.45 average for $22.7 million gross and $22.3 million net; year-to-date 1,092,798 shares for $35.4 million net, leaving $63.9 million available on the $100 million program.
-
Cash Runway Past APEX Readout
Cash and equivalents of $234.7 million at September 30, 2026, with management stating resources fund operations beyond twelve months from issuance and no going-concern doubt.
-
APEX Phase 2 Data Due January 2027
Enrollment of 191 patients completed June 2026 and the IDMC recommended continuation in July 2026; topline TX45 results in PH-HFpEF are expected by end of January 2027.
Analysis · TECX · Life Sciences
The headline numbers match this morning's 8-K, but the 10-Q is where the capital structure actually gets quantified. Tectonic sold 660,492 shares under its ATM in Q3 at a $34.45 average, raising $22.3M net, and has now sold 1,092,798 shares for $35.4M net year-to-date. That is real dilution already executed, not a shelf authorization — share count rose to 19,935,375 from 18,738,249 at year-end. Against that, $234.7M of cash with no going-concern language and a stated runway beyond twelve months means the company is funded well past the January 2027 APEX Phase 2 readout, which is the event that will actually reprice the stock.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECX was trading at $19.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.6M. The 52-week trading range was $15.52 to $39.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.